1. Lepor H. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol 2004;6(Suppl 9):S3-10.
2. Hoke GP, McWilliams GW. Epidemiology of benign prostatic hyperplasia and comorbidities in racial and ethnic minority populations. Am J Med 2008;121(8 Suppl 2):S3-10.
3. Auffenberg GB, Helfand BT, McVary KT. Established medical therapy for benign prostatic hyperplasia. Urol Clin North Am 2009;36:443-59; v-vi.
4. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004;46:547-54.
5. Chapple CR. Alpha adrenoceptor antagonists in the year 2000: is there anything new? Curr Opin Urol 2001;11:9-16.
6. Marberger M, Harkaway R, de la Rosette J. Optimising the medical management of benign prostatic hyperplasia. Eur Urol 2004;45:411-9.
7. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL. . The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998;338:557-63.
8. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD. . The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992;327:1185-91.
9. Wessells H, Roy J, Bannow J, Grayhack J, Matsumoto AM, Tenover L. . Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology 2003;61:579-84.
10. Casabé A, Roehrborn CG, Da Pozzo LF, Zepeda S, Henderson RJ, Sorsaburu S. . Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol 2014;191:727-33.
11. Chung JH, Kang DH, Oh CY, Chung JM, Lee KS, Kim TH. . Safety and efficacy of once daily administration of 50 mg mirodenafil in patients with erectile dysfunction: a multi-center, double-blind, placebo controlled trial. J Urol 2013;189:1006-13.
12. Konstantinopoulos A, Giannitsas K, Athanasopoulos A, Spathas D, Perimenis P. The impact of daily sildenafil on levels of soluble molecular markers of endothelial function in plasma in patients with erectile dysfunction. Expert Opin Pharmacother 2009;10:155-60.
13. Porst H, Kim ED, Casabé AR, Mirone V, Secrest RJ, Xu L. . Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol 2011;60:1105-13.
14. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G. . The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996;335:533-9.
15. Egerdie RB, Auerbach S, Roehrborn CG, Costa P, Garza MS, Esler AL. . Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med 2012;9:271-81.
16. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008;180:1228-34.
17. Zhao C, Kim SW, Yang DY, Kim JJ, Park NC, Lee SW. . Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2011;60:380-7.
18. Zhao C, Kim SH, Lee SW, Jeon JH, Kang KK, Choi SB. . Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int 2011;107:1943-7.
19. Lee SK, Kim Y, Kim TK, Im GJ, Lee BY, Kim DH. . Determination of mirodenafil and sildenafil in the plasma and corpus cavernous of SD male rats. J Pharm Biomed Anal 2009;49:513-8.
20. Borin MT, Hughes GS, Patel RK, Royer ME, Cathcart KS. Pharmacokinetic and tolerance studies of cefpodoxime after single- and multiple-dose oral administration of cefpodoxime proxetil. J Clin Pharmacol 1991;31:1137-45.
21. Zhanel GG, Craig WA. Pharmacokinetic contributions to postantibiotic effects. Focus on aminoglycosides. Clin Pharmacokinet 1994;27:377-92.